Endocrine and hormonal research
PT-141
Also known as Bremelanotide
A melanocortin receptor agonist that acts on central nervous system pathways, with an approved clinical indication in the United States.
What it is
PT-141 is a synthetic analogue of alpha-melanocyte-stimulating hormone that activates melanocortin receptors, principally MC3R and MC4R, in the central nervous system. It emerged from research into a related compound and holds FDA approval under the brand name Vyleesi for a specific indication.
What published research examines
- Melanocortin receptor signalling in the central nervous system
- Hypothalamic pathways, a mechanism distinct from vascular-acting compounds
- Appetite and energy balance, a separate line of melanocortin research
- Blood pressure response, a documented consideration in the clinical literature
Where the research stands
PT-141 has been through controlled clinical trials and is approved for one narrow indication, giving it a more developed evidence base than most compounds in this catalogue.